Construction of a lung adenocarcinoma prognostic model based on KEAP1/NRF2/HO‑1 mutation‑mediated upregulated genes and bioinformatic analysis

Zhu,Wei; Zhang,Ye; Yang,Lingyun; Chen,Lu; Chen,Chaobo; Shi,Qifeng; Xu,Zipeng

doi:10.3892/ol.2025.14902

Construction of a lung adenocarcinoma prognostic model based on KEAP1/NRF2/HO‑1 mutation‑mediated upregulated genes and bioinformatic analysis

Authors:
- Wei Zhu
- Ye Zhang
- Lingyun Yang
- Lu Chen
- Chaobo Chen
- Qifeng Shi
- Zipeng Xu
View Affiliations

Affiliations: Department of Pathology, Xishan People's Hospital of Wuxi City, Wuxi, Jiangsu 214105, P.R. China, Department of Renal and Rheumatology, Affiliated Children's Hospital of Jiangnan University (Wuxi Children's Hospital), Wuxi, Jiangsu 214000, P.R. China, Department of General Surgery, Xishan People's Hospital of Wuxi City, Wuxi, Jiangsu 214105, P.R. China
Published online on: January 23, 2025 https://doi.org/10.3892/ol.2025.14902
Article Number: 155
Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung adenocarcinoma (LUAD) is a prevalent malignant tumor of the respiratory tract. The Kelch like ECH associated protein 1 (KEAP1)/nuclear factor erythroid 2‑related factor 2 (NRF2)/heme oxygenase 1 (HO‑1) axis serves a pivotal role in the occurrence and progression of LUAD. The present study aimed to identify specific genes regulated by mutations of the KEAP1/NRF2/HO‑1 axis and to investigate their prognostic potential in LUAD, as well as their association with the tumor microenvironment. Immunohistochemistry was performed to assess the expression levels of KEAP1, NRF2 and HO‑1 in LUAD tissues and to evaluate their association with clinical pathology. Sequencing data and clinical information were obtained from The Cancer Genome Atlas (TCGA)‑LUAD and Gene Expression Omnibus (GSE68465) databases, whilst mutation information was sourced from the cBio Cancer Genomics Portal website. The R package ‘limma’ and Venn diagram were utilized to identify upregulated differentially expressed genes. Subsequently, a prognostic model was constructed using univariate Cox regression analysis and 101 machine learning methods. A nomogram of the prognostic model was generated to assess its efficacy in evaluating survival among patients with LUAD. The ‘ImmuCellAI’ and ‘oncoPredict’ R packages were used to compare and evaluate differences in immune cell infiltration and immunotherapy between high‑ and low‑risk groups, as well as the sensitivity of LUAD to chemotherapy drugs. Compared with the group with negative expression, the results revealed that the group with positive expression of NRF2 and HO‑1 exhibited advanced tumor, lymph node and clinical stages and a worse prognosis. A predictive model incorporating four genes (kynureninase, serpin family B member 5, insulin like 4 and γ‑aminobutyric acid type A receptor subunit α3) was constructed based on KEAP1/NRF2/HO‑1 mutation‑mediated upregulated genes (KNHMUGs). Risk score was an independent prognostic factor for patients with LUAD (hazard ratio, 1.038; 95% confidence interval, 1.034‑1.043; P<0.001). A nomogram was developed to predict the prognosis of patients with LUAD, which was validated as a reliable prognostic tool. The low‑risk group exhibited higher immune cell infiltration, including CD4+ T, CD8+ T, natural killer (NK) and NKT cells, compared with the high‑risk group. In addition, it demonstrated increased expression levels of immune checkpoint inhibitory genes such as cytotoxic T‑lymphocyte associated protein 4, T cell immunoreceptor with Ig and ITIM domains, hepatitis A virus cellular receptor 2 and B and T lymphocyte associated protein. Moreover, it displayed enhanced sensitivity to immunotherapy. Drug sensitivity analysis revealed that the high‑risk group exhibited increased sensitivity towards vinblastine, docetaxel and cisplatin, whereas the low‑risk group showed increased sensitivity to BMS_754807, SB505124_1194 and JQ1_2172. In conclusion, a KNHMUGs‑based gene signature was constructed in the present study, which holds promise as a biomarker for evaluating patient prognosis and guiding treatment by effectively assessing immunotherapy response and chemotherapy sensitivity in patients with LUAD.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Denisenko TV, Budkevich IN and Zhivotovsky B: Cell death-based treatment of lung adenocarcinoma. Cell Death Dis. 9:1172018. View Article : Google Scholar : PubMed/NCBI
3	Reck M and Rabe KF: Precision diagnosis and treatment for advanced non-small-cell lung cancer. N Engl J Med. 377:849–861. 2017. View Article : Google Scholar : PubMed/NCBI
4	Li Y, Yan B and He S: Advances and challenges in the treatment of lung cancer. Biomed Pharmacother. 169:1158912023. View Article : Google Scholar : PubMed/NCBI
5	Obradovic J, Todosijevic J and Jurisic V: Application of the conventional and novel methods in testing EGFR variants for NSCLC patients in the last 10 years through different regions: A systematic review. Mol Biol Rep. 48:3593–3604. 2021. View Article : Google Scholar : PubMed/NCBI
6	Jurisic V, Vukovic V, Obradovic J, Gulyaeva LF, Kushlinskii NE and Djordjevic N: EGFR polymorphism and survival of NSCLC patients treated with TKIs: A systematic review and meta-analysis. J Oncol. 2020:19732412020. View Article : Google Scholar : PubMed/NCBI
7	Obradovic J, Todosijevic J and Jurisic V: Side effects of tyrosine kinase inhibitors therapy in patients with non-small cell lung cancer and associations with EGFR polymorphisms: A systematic review and meta-analysis. Oncol Lett. 25:622023. View Article : Google Scholar : PubMed/NCBI
8	Xu K, Ma J, Hall SRR, Pengs RW, Yang H and Yao F: Battles against aberrant KEAP1-NRF2 signaling in lung cancer: Intertwined metabolic and immune networks. Theranostics. 13:704–723. 2023. View Article : Google Scholar : PubMed/NCBI
9	Ghareghomi S, Moosavi-Movahedi F, Saso L, Habibi-Rezaei M, Khatibi A, Hong J and Moosavi-Movahedi AA: Modulation of Nrf2/HO-1 by natural compounds in lung cancer. Antioxidants (Basel). 12:7352023. View Article : Google Scholar : PubMed/NCBI
10	Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, et al: Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 150:1107–1120. 2012. View Article : Google Scholar : PubMed/NCBI
11	Romero R, Sanchez-Rivera FJ, Westcott PMK, Mercer KL, Bhutkar A, Muir A, Robles TJ, Rodriguez SL, Liao LZ, Ng SR, et al: Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1. Nat Cancer. 1:589–602. 2020. View Article : Google Scholar : PubMed/NCBI
12	Romero R, Sayin VI, Davidson SM, Bauer MR, Singh SX, LeBoeuf SE, Karakousi TR, Ellis DC, Bhutkar A, Sanchez-Rivera FJ, et al: Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat Med. 23:1362–1368. 2017. View Article : Google Scholar : PubMed/NCBI
13	Zavitsanou AM, Pillai R, Hao Y, Wu WL, Bartnicki E, Karakousi T, Rajalingam S, Herrera A, Karatza A, Rashidfarrokhi A, et al: KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance. Cell Rep. 42:1132952023. View Article : Google Scholar : PubMed/NCBI
14	Ghareghomi S, Habibi-Rezaei M, Arese M, Saso L and Moosavi-Movahedi AA: Nrf2 modulation in breast cancer. Biomedicines. 10:26682022. View Article : Google Scholar : PubMed/NCBI
15	Menegon S, Columbano A and Giordano S: The dual roles of NRF2 in cancer. Trends Mol Med. 22:578–593. 2016. View Article : Google Scholar : PubMed/NCBI
16	Kerins MJ and Ooi A: A catalogue of somatic NRF2 gain-of-function mutations in cancer. Sci Rep. 8:128462018. View Article : Google Scholar : PubMed/NCBI
17	Li C, Liang G, Yan K and Wang Y: NRF2 mutation enhances the immune escape of hepatocellular carcinoma by reducing STING activation. Biochem Biophys Res Commun. 698:1495362024. View Article : Google Scholar : PubMed/NCBI
18	Tang H, Liu S, Yan X, Jin Y, He X, Huang H, Liu L, Hu W and Wu A: Inhibition of LNC EBLN3P enhances radiation-induced mitochondrial damage in lung cancer cells by targeting the Keap1/Nrf2/HO-1 axis. Biology (Basel). 12:12082023.PubMed/NCBI
19	Spampinato M, Sferrazzo G, Pittala V, Di Rosa M, Vanella L, Salerno L, Sorrenti V, Carota G, Parrinello N, Raffaele M, et al: Non-competitive heme oxygenase-1 activity inhibitor reduces non-small cell lung cancer glutathione content and regulates cell proliferation. Mol Biol Rep. 47:1949–1964. 2020. View Article : Google Scholar : PubMed/NCBI
20	Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma, Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, et al: Gene expression-based survival prediction in lung adenocarcinoma: A multi-site, blinded validation study. Nat Med. 14:822–827. 2008. View Article : Google Scholar
21	Lanczky A and Gyorffy B: Web-based survival analysis tool tailored for medical research (KMplot): Development and implementation. J Med Internet Res. 23:e276332021. View Article : Google Scholar : PubMed/NCBI
22	Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W and Smyth GK: limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43:e472015. View Article : Google Scholar : PubMed/NCBI
23	Liu Z, Liu L, Weng S, Guo C, Dang Q, Xu H, Wang L, Lu T, Zhang Y, Sun Z and Han X: Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer. Nat Commun. 13:8162022. View Article : Google Scholar : PubMed/NCBI
24	Miao YR, Zhang Q, Lei Q, Luo M, Xie GY, Wang H and Guo AY: ImmuCellAI: A unique method for comprehensive T-cell subsets abundance prediction and its application in cancer immunotherapy. Adv Sci (Weinh). 7:19028802020. View Article : Google Scholar : PubMed/NCBI
25	Maeser D, Gruener RF and Huang RS: oncoPredict: An R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 22:bbab2602021. View Article : Google Scholar : PubMed/NCBI
26	Detterbeck FC, Woodard GA, Bader AS, Dacic S, Grant MJ, Park HS and Tanoue LT: The proposed ninth edition TNM classification of lung cancer. Chest. 166:882–895. 2024. View Article : Google Scholar : PubMed/NCBI
27	Lou JS, Zhao LP, Huang ZH, Chen XY, Xu JT, Tai WC, Tsim KWK, Chen YT and Xie T: Ginkgetin derived from Ginkgo biloba leaves enhances the therapeutic effect of cisplatin via ferroptosis-mediated disruption of the Nrf2/HO-1 axis in EGFR wild-type non-small-cell lung cancer. Phytomedicine. 80:1533702021. View Article : Google Scholar : PubMed/NCBI
28	Bi G, Liang J, Zhao M, Zhang H, Jin X, Lu T, Zheng Y, Bian Y, Chen Z, Huang Y, et al: miR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma via CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways. Mol Ther Nucleic Acids. 28:366–386. 2022. View Article : Google Scholar : PubMed/NCBI
29	Mei L, Long J, Wu S, Mei M, Mei D and Qiu H: APOC1 reduced anti-PD-1 immunotherapy of nonsmall cell lung cancer via the transformation of M2 into M1 macrophages by ferroptosis by NRF2/HO-1. Anticancer Drugs. 35:333–343. 2024. View Article : Google Scholar : PubMed/NCBI
30	Wei XW, Lu C, Zhang YC, Fan X, Xu CR, Chen ZH, Wang F, Yang XR, Deng JY, Yang M, et al: Redox(high) phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinoma. Oncoimmunology. 13:23401542024. View Article : Google Scholar : PubMed/NCBI
31	Fahrmann JF, Tanaka I, Irajizad E, Mao X, Dennison JB, Murage E, Casabar J, Mayo J, Peng Q, Celiktas M, et al: Mutational activation of the NRF2 pathway upregulates kynureninase resulting in tumor immunosuppression and poor outcome in lung adenocarcinoma. Cancers (Basel). 14:25432022. View Article : Google Scholar : PubMed/NCBI
32	Phillips RS: Structure and mechanism of kynureninase. Arch Biochem Biophys. 544:69–74. 2014. View Article : Google Scholar : PubMed/NCBI
33	Karayama M, Masuda J, Mori K, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, et al: Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer. Clin Transl Oncol. 23:418–423. 2021. View Article : Google Scholar : PubMed/NCBI
34	Leon-Letelier RA, Sater AH, Chen Y, Srejbhjv S, et al: Kynureninase upregulation is a prominent feature of NFR2-activated cancers and is associated with tumor immunosuppression and poor prognosis. Cancers (Basel). 15:8342023. View Article : Google Scholar : PubMed/NCBI
35	Liu BX, Xie Y, Zhang J, Zeng S, Li J, Tao Q, Yang J, Chen Y and Zeng C: SERPINB5 promotes colorectal cancer invasion and migration by promoting EMT and angiogenesis via the TNF-α/NF-κB pathway. Int Immunopharmacol. 131:1117592024. View Article : Google Scholar : PubMed/NCBI
36	Rathod M, Franz H, Beyersdorfer V, Wanuske MT, Leal-Fischer K, Hanns P, Stüdle C, Zimmermann A, Buczak K, Schinner C and Spindler V: DPM1 modulates desmosomal adhesion and epidermal differentiation through SERPINB5. J Cell Biol. 223:e2023050062024. View Article : Google Scholar : PubMed/NCBI
37	He X, Ma Y, Huang Z, Wang G, Wang W, Zhang R, Guo G, Zhang X, Wen Y and Zhang L: SERPINB5 is a prognostic biomarker and promotes proliferation, metastasis and epithelial-mesenchymal transition (EMT) in lung adenocarcinoma. Thorac Cancer. 14:2275–2287. 2023. View Article : Google Scholar : PubMed/NCBI
38	Scopetti D, Piobbico D, Brunacci C, Pieroni S, Bellezza G, Castelli M, Ludovini V, Tofanetti FR, Cagini L, Sidoni A, et al: INSL4 as prognostic marker for proliferation and invasiveness in non-small-cell lung cancer. J Cancer. 12:3781–3795. 2021. View Article : Google Scholar : PubMed/NCBI
39	Yang R, Li SW, Chen Z, Zhou X, Ni W, Fu DA, Lu J, Kaye FJ and Wu L: Role of INSL4 signaling in sustaining the growth and viability of LKB1-inactivated lung cancer. J Natl Cancer Inst. 111:664–674. 2019. View Article : Google Scholar : PubMed/NCBI
40	Bhattacharya D, Gawali VS, Kallay L, Toukam DK, Koehler A, Stambrook P, Krummel DP and Sengupta S: Therapeutically leveraging GABA(A) receptors in cancer. Exp Biol Med (Maywood). 246:2128–2135. 2021. View Article : Google Scholar : PubMed/NCBI
41	Liu L, Yang C, Shen J, Huang L, Lin W, Tang H, Liang W, Shao W, Zhang H and He J: GABRA3 promotes lymphatic metastasis in lung adenocarcinoma by mediating upregulation of matrix metalloproteinases. Oncotarget. 7:32341–32350. 2016. View Article : Google Scholar : PubMed/NCBI
42	Hanahan D and Coussens LM: Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell. 21:309–322. 2012. View Article : Google Scholar : PubMed/NCBI
43	Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, et al: Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 24:541–550. 2018. View Article : Google Scholar : PubMed/NCBI
44	Genova C, Dellepiane C, Carrega P, Sommariva S, Ferlazzo G, Pronzato P, Gangemi R, Filaci G, Coco S and Croce M: Therapeutic implications of tumor microenvironment in lung cancer: Focus on immune checkpoint blockade. Front Immunol. 12:7994552021. View Article : Google Scholar : PubMed/NCBI
45	Song P, Li W, Guo L, Ying J, Gao S and He J: Identification and validation of a novel signature based on NK cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma by integrated analysis of single-cell and bulk RNA-sequencing. Front Immunol. 13:8507452022. View Article : Google Scholar : PubMed/NCBI
46	Terabe M and Berzofsky JA: Tissue-specific roles of NKT cells in tumor immunity. Front Immunol. 9:18382018. View Article : Google Scholar : PubMed/NCBI
47	Rad SH, Monkman J, Warkiani ME, Ladwa R, O'Byrne K, Rezaei N and Kulasinghe A: Understanding the tumor microenvironment for effective immunotherapy. Med Res Rev. 41:1474–1498. 2021. View Article : Google Scholar : PubMed/NCBI
48	Ge Z, Peppelenbosch MP, Sprengers D and Kwekkeboom J: TIGIT, the next step towards successful combination immune checkpoint therapy in cancer. Front Immunol. 12:6998952021. View Article : Google Scholar : PubMed/NCBI
49	Acharya N, Sabatos-Peyton C and Anderson AC: Tim-3 finds its place in the cancer immunotherapy landscape. J Immunother Cancer. 8:e0009112020. View Article : Google Scholar : PubMed/NCBI
50	Wojciechowicz K, Spodzieja M and Wardowska A: The BTLA-HVEM complex-The future of cancer immunotherapy. Eur J Med Chem. 268:1162312024. View Article : Google Scholar : PubMed/NCBI
51	Gebbia V, Lorusso V, Galetta D, Caruso MM, Palomba G, Riccardi F, Borsellino N, Carrozza F, Leo S, Ferraù F, et al: First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: A quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale. Lung Cancer. 69:218–224. 2010. View Article : Google Scholar : PubMed/NCBI
52	Fuentes-Baile M, Ventero MP, Encinar JA, García-Morales P, Poveda-Deltell M, Pérez-Valenciano E, Barberá VM, Gallego-Plazas J, Rodríguez-Lescure Á, Martín-Nieto J and Saceda M: Differential effects of IGF-1r small molecule tyrosine kinase inhibitors BMS-754807 and OSI-906 on human cancer cell lines. Cancers (Basel). 12:37172020. View Article : Google Scholar : PubMed/NCBI
53	Zhang C, Zhao X, Wang Z, Gong T, Zhao H, Zhang D, Niu Y, Li X, Zhao X, Li G, et al: Dasatinib in combination with BMS-754807 induce synergistic cytotoxicity in lung cancer cells through inhibiting lung cancer cell growth, and inducing autophagy as well as cell cycle arrest at the G1 phase. Invest New Drugs. 41:438–452. 2023. View Article : Google Scholar : PubMed/NCBI
54	DaCosta Byfield S, Major C, Laping NJ and Roberts AB: SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 65:744–752. 2004. View Article : Google Scholar : PubMed/NCBI
55	Wu TH, Chou YW, Chiu PH, Tang MJ, Hu CW and Yeh ML: Validation of the effects of TGF-β1 on tumor recurrence and prognosis through tumor retrieval and cell mechanical properties. Cancer Cell Int. 14:202014. View Article : Google Scholar : PubMed/NCBI
56	Stathis A and Bertoni F: BET proteins as targets for anticancer treatment. Cancer Discov. 8:24–36. 2018. View Article : Google Scholar : PubMed/NCBI
57	Wang J, Xu Y, Rao X, Zhang R, Tang J, Zhang D, Jie X, Zhu K, Wang X, Xu Y, et al: BRD4-IRF1 axis regulates chemoradiotherapy-induced PD-L1 expression and immune evasion in non-small cell lung cancer. Clin Transl Med. 12:e7182022. View Article : Google Scholar : PubMed/NCBI
58	Mrdjanovic J, Solajic S, Srdenovic-Conic B, Bogdanović V, Dea KJ, Kladar N and Jurišić V: The oxidative stress parameters as useful tools in evaluating the DNA damage and changes in the complete blood count in hospital workers exposed to low doses of antineoplastic drugs and ionizing radiation. Int J Environ Res Public Health. 18:84452021. View Article : Google Scholar : PubMed/NCBI